BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12846921)

  • 21. Changes to the Pharmaceutical Benefits Advisory Committee.
    Henry DA; Birkett DJ
    Med J Aust; 2001 Mar; 174(5):209-10. PubMed ID: 11280687
    [No Abstract]   [Full Text] [Related]  

  • 22. [Drug expenditures and health insurance contributions increase. Control of budgetsis at risk].
    Jentsch P
    MMW Fortschr Med; 2001 Jul; 143(26-27):49-50. PubMed ID: 11481918
    [No Abstract]   [Full Text] [Related]  

  • 23. [Expenditures on medicines by the Rio de Janeiro Municipal Health Department, Brazil, 2002-2011].
    Silva RM; Caetano R
    Cad Saude Publica; 2014 Jun; 30(6):1207-18. PubMed ID: 25099044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Incentives for especially cost effective prescribing. The physician protects his budget, the patient saves co-pay].
    Schmidt K
    MMW Fortschr Med; 2006 Nov; 148(44):57, 59. PubMed ID: 17619443
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparative approaches to pharmaceutical price regulation in the European Union.
    Mrazek MF
    Croat Med J; 2002 Aug; 43(4):453-61. PubMed ID: 12187524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug costs in Canada.
    Fuller S
    Health Aff (Millwood); 2003; 22(4):259. PubMed ID: 12889774
    [No Abstract]   [Full Text] [Related]  

  • 27. Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia.
    Morgan SG; Agnew JD; Barer ML
    Health Policy; 2004 Jun; 68(3):299-307. PubMed ID: 15113641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmaceutical management strategies of industrialized countries.
    Brier KL
    Formulary; 1995 Oct; 30(10):606-10, 614. PubMed ID: 10151724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and localisation of casemix applications for inpatient hospital activity in EU member states.
    Wiley MM
    Aust Health Rev; 1999; 22(2):69-85. PubMed ID: 10558298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Increasing drug costs. The society's drug expenditures are strongly increasing. If this trend continues we have to make other priorities].
    Andreasen J
    Ugeskr Laeger; 2003 Jul; 165(29):2873-6. PubMed ID: 12908355
    [No Abstract]   [Full Text] [Related]  

  • 31. [Millions of old cost burdens. The time bomb of overdue drug budgets].
    Bossmann A
    Chirurg; 1998 Apr; 69(4):suppl 116-8. PubMed ID: 9612626
    [No Abstract]   [Full Text] [Related]  

  • 32. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficient use of pharmaceuticals: does Europe have any lessons for a Medicare drug benefit?
    Towse A
    Health Aff (Millwood); 2003; 22(3):42-5. PubMed ID: 12757270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expenditures for prescription drugs: too much or not enough?
    Schumock GT; Walton SM
    Healthc Financ Manage; 2003 Oct; 57(10):34-8, 41. PubMed ID: 14560578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of a price cut reform on the cost and utilization of antidiabetic drugs in Korea: a national health insurance database study.
    Suh HS; Kim JA; Lee IH
    BMC Health Serv Res; 2018 Jun; 18(1):429. PubMed ID: 29879966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prescription drugs: recent trends in utilization, expenditures, and coverage.
    Sethi RC
    EBRI Issue Brief; 2004 Jan; (265):1-35. PubMed ID: 14969223
    [No Abstract]   [Full Text] [Related]  

  • 37. [The budget control function of the Drug Reimbursement System].
    Vooren PH
    Ned Tijdschr Geneeskd; 2002 Nov; 146(47):2264-5. PubMed ID: 12481525
    [No Abstract]   [Full Text] [Related]  

  • 38. Hospital ownership and drug utilization under a global budget: a quantile regression analysis.
    Zhang JH; Chou SY; Deily ME; Lien HM
    Int Health; 2014 Mar; 6(1):62-9. PubMed ID: 24526003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmaceutical expenditure in Spain: cost and control.
    Lopez Bastida J; Mossialos E
    Int J Health Serv; 2000; 30(3):597-616. PubMed ID: 11109184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study shows increases in drug costs may be justified by improvements in outcomes.
    Capitation Rates Data; 2000 Jun; 5(6):65-8. PubMed ID: 11067438
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.